^
    2d
    Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (clinicaltrials.gov)
    P2, N=720, Recruiting, Canadian Cancer Trials Group | Trial primary completion date: Jan 2026 --> Dec 2026
    Trial primary completion date • Tumor mutational burden • Pan tumor
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)
    3d
    Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis (clinicaltrials.gov)
    P2, N=73, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2028 --> Feb 2026 | Trial primary completion date: Jan 2028 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    axitinib
    4d
    Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Columbia University | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    |
    VHL mutation
    |
    axitinib
    12d
    A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST (2024-519176-95-00)
    P1/2, N=58, Completed, Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy | Active, not recruiting --> Completed
    Trial completion
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    KIT mutation • PDGFRA mutation
    |
    Bavencio (avelumab) • axitinib
    16d
    Axitinib and Nivolumab for the Treatment of Mucosal Melanoma (clinicaltrials.gov)
    P2, N=20, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • axitinib
    19d
    Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations. (PubMed, Front Oncol)
    He underwent nephrectomy, followed by hepatic recurrence treated with pazopanib and subsequent axitinib. Based on these findings, everolimus, a mammalian/mechanistic target of rapamycin (mTOR) inhibitor, was recommended, which markedly reduced the size of the metastatic lesions and was continued for 24 months until disease progression without severe adverse events. This case suggests that CGP can help identify actionable alterations in eAML, such as TSC2 mutations, to guide personalized therapy with mTOR inhibitors.
    Journal
    |
    TSC2 (TSC complex subunit 2)
    |
    everolimus • pazopanib • axitinib • sirolimus
    19d
    A Case of Cytokine Release Syndrome Induced by Avelumab and Axitinib Combination Therapy for Metastatic Renal Cell Carcinoma. (PubMed, IJU Case Rep)
    The patient was successfully treated with corticosteroids and tocilizumab. This is the first report of CRS associated with avelumab-axitinib therapy in RCC and highlights the importance of early recognition and distinction from IRR, especially when COVID-19 coexists.
    Journal
    |
    IL6 (Interleukin 6) • CRP (C-reactive protein)
    |
    Bavencio (avelumab) • axitinib • Actemra IV (tocilizumab)
    22d
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=199, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Jul 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • axitinib • tiragolumab (RG6058) • tobemstomig (RG6139)
    26d
    Integration of single-cell sequencing, transcriptome sequencing, and machine learning for constructing and validating histone acetylation-related prognostic risk models in hepatocellular carcinoma. (PubMed, Front Immunol)
    Chemosensitivity analysis showed that the high-risk group had increased sensitivity to four drugs, including Axitinib, but decreased sensitivity to 21 drugs, including Cisplatin...Molecular docking revealed that five compounds, including Oseltamivir, could bind directly to NEU1. Knockdown of NEU1 significantly reduced proliferation, migration, and invasion of LIHC cells, and slowed LIHC tumor growth. We constructed a histone acetylation-based risk model for LIHC diagnosis, prognosis, and therapy, identifying NEU1 as a key biomarker and potential therapeutic target.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    NPM1 (Nucleophosmin 1) • CDK4 (Cyclin-dependent kinase 4) • B2M (Beta-2-microglobulin) • PD-L2 (Programmed Cell Death 1 Ligand 2) • GPX4 (Glutathione Peroxidase 4) • HLA-B (Major Histocompatibility Complex, Class I, B) • ACAT1 (Acetyl-CoA Acetyltransferase 1) • HSPD1 (Heat Shock Protein Family D (Hsp60) Member 1) • METTL3 (Methyltransferase Like 3) • PON1 (Paraoxonase 1)
    |
    cisplatin • axitinib
    1m
    Clinical Outcomes of Targeted Therapies Following HIF-2α Inhibition in Metastatic Renal Cell Carcinoma: A Real-World Analysis. (PubMed, Clin Genitourin Cancer)
    Despite extensive prior treatment, patients experienced clinical benefit from TT, particularly VEGFR-TKIs, after progression on belzutifan. These findings support the feasibility of sequencing TT following belzutifan-based regimens in advanced ccRCC, and highlight the need to further define optimal therapeutic sequencing strategies.
    Clinical data • Journal • Real-world evidence
    |
    EPAS1 (Endothelial PAS domain protein 1)
    |
    everolimus • Cabometyx (cabozantinib tablet) • axitinib • Welireg (belzutifan)
    1m
    Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer (clinicaltrials.gov)
    P3, N=718, Not yet recruiting, SWOG Cancer Research Network
    New P3 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • axitinib • ABP 206 (nivolumab biosimilar) • Cdactin-O (CBM588) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    1m
    KEYNOTE 426: Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) (clinicaltrials.gov)
    P3, N=861, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • sunitinib • axitinib